Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

ABEO

Abeona Therapeutics Inc

Nov 08 • 04:00PM ET

6.40

Dollar change +0.02
Percentage change 0.31	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN QURE SRPT SGMO BLUE CLGN ADVM FATE VYGR NTLA

| Held by: VTI VXF SURI IWC IBRN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.55	Insider Own	9.50%	Shs Outstand	43.31M	Perf Week	2.40%
Market Cap	278.08M	Forward P/E	-	EPS next Y	-1.39	Insider Trans	-0.98%	Shs Float	39.20M	Perf Month	-2.74%
Income	-52.60M	PEG	-	EPS next Q	-0.39	Inst Own	76.26%	Short Float	7.07%	Perf Quarter	29.29%
Sales	0.00M	P/S	-	EPS this Y	39.33%	Inst Trans	269.19%	Short Ratio	11.18	Perf Half Y	52.38%
Book/sh	1.76	P/B	3.64	EPS next Y	9.28%	ROA	-56.09%	Short Interest	2.77M	Perf Year	50.23%
Cash/sh	2.83	P/C	2.26	EPS next 5Y	-	ROE	-127.38%	52W Range	3.05 - 9.01	Perf YTD	27.74%
Dividend Est.	-	P/FCF	-	EPS past 5Y	38.92%	ROI	-56.93%	52W High	-28.97%	Beta	1.44
Dividend TTM	-	Quick Ratio	7.48	Sales past 5Y	-15.07%	Gross Margin	13.31%	52W Low	109.84%	ATR (14)	0.29
Dividend Ex-Date	-	Current Ratio	7.48	EPS Y/Y TTM	30.17%	Oper. Margin	0.00%	RSI (14)	52.98	Volatility	4.29% 4.69%
Employees	84	Debt/Eq	0.32	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	15.92
Option/Short	Yes / Yes	LT Debt/Eq	0.26	EPS Q/Q	71.60%	Payout	-	Rel Volume	0.79	Prev Close	6.38
Sales Surprise	-100.00%	EPS Surprise	23.98%	Sales Q/Q	-100.00%	Earnings	Aug 12 BMO	Avg Volume	247.70K	Price	6.40
SMA20	-0.19%	SMA50	4.55%	SMA200	12.41%	Trades		Volume	194,982	Change	0.31%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-03-24	Initiated	H.C. Wainwright	Buy	$15
May-30-24	Initiated	Stifel	Buy	$21
Nov-11-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$4
Sep-18-20	Initiated	B. Riley FBR	Buy	$5
Feb-10-20	Initiated	SVB Leerink	Outperform	$6
Dec-10-19	Resumed	Cantor Fitzgerald	Neutral	$2 → $4
Aug-15-19	Downgrade	Maxim Group	Buy → Hold
Aug-12-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$29 → $2
Jul-26-19	Downgrade	Mizuho	Buy → Neutral	$17 → $4
Jun-27-19	Initiated	Mizuho	Buy
Oct-12-18	Initiated	Mizuho	Buy	$17
Jun-05-18	Initiated	Seaport Global Securities	Buy	$29
Nov-08-17	Initiated	SunTrust	Buy	$26
Oct-16-17	Reiterated	H.C. Wainwright	Buy	$20 → $30
Oct-11-17	Reiterated	Cantor Fitzgerald	Overweight	$21 → $34
Oct-10-17	Initiated	Citigroup	Buy	$32
Oct-05-17	Reiterated	Maxim Group	Buy	$17 → $35
Sep-15-17	Initiated	RBC Capital Mkts	Outperform	$23
Jul-18-17	Reiterated	Maxim Group	Buy	$14 → $17
Jun-22-17	Resumed	Jefferies	Buy	$22

Show Previous Ratings

Nov-04-24 07:30AM	Abeona Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire)
Nov-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-29-24 07:30AM	Abeona Therapeutics Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration (GlobeNewswire)
Oct-09-24 06:13PM	Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... (GuruFocus.com)
Oct-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:30AM	Loading…
Sep-03-24 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-02-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-24 07:30AM	Abeona Therapeutics Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors (GlobeNewswire)
Aug-13-24 07:30AM	Abeona Therapeutics Announces Favorable Medicare Reimbursement Decisions for Pz-cel (GlobeNewswire)
Aug-12-24 07:37AM	Abeona Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +11.99%
07:30AM	Abeona Therapeutics Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission (GlobeNewswire)
Aug-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-11-24 07:30AM	Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications (GlobeNewswire)
Jul-08-24 07:30AM	Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum (GlobeNewswire) +5.73%
Jun-21-24 03:08AM	Insider Sale: Director Christine Silverstein Sells Shares of Abeona Therapeutics Inc (ABEO) (GuruFocus.com)
07:30AM	Loading…
Jun-03-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-24 07:30AM	Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 03:01AM	Abeona Therapeutics Inc (ABEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ... (GuruFocus.com)
02:17AM	Q1 2024 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-24 12:53PM	ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +12.14%
07:43AM	Abeona Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress (GlobeNewswire)
May-07-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-03-24 11:19AM	Abeona Therapeutics Prices $75 Million Securities Offering; Shares Rise (MT Newswires) +13.02%
07:30AM	Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Apr-23-24 02:04PM	Top Midday Decliners (MT Newswires) -53.67%
08:53AM	Why Is Abeona Therapeutics (ABEO) Stock Down 45% Today? (InvestorPlace)
07:39AM	Top Premarket Decliners (MT Newswires)
07:09AM	FDA rejects Abeona cell therapy, asks for more manufacturing data (BioPharma Dive)
Apr-22-24 05:58PM	Abeona Therapeutics Shares Slump After Plans to Reapply for Pz-cel Drug Approval (MT Newswires)
04:27PM	Loading…
04:27PM	UPDATE 1-US FDA declines to approve Abeona's skin disorder treatment (Reuters)
04:14PM	US FDA declines to approve Abeona's skin disorder treatment (Reuters)
04:05PM	Abeona Therapeutics Provides Regulatory Update on Pz-cel (GlobeNewswire)
Apr-01-24 08:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.48%
Mar-19-24 06:53AM	ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +8.30%
05:31AM	Abeona Therapeutics Inc (ABEO) Reports Full Year 2023 Financial Results (GuruFocus.com)
Mar-18-24 07:30AM	Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections (GlobeNewswire) -19.00%
Mar-05-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.32%
Feb-15-24 05:52AM	Steven Cohen's Firm Increases Stake in Abeona Therapeutics Inc (GuruFocus.com) +5.53%
Feb-01-24 04:05PM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.65%
07:30AM	Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA) (GlobeNewswire)
Jan-08-24 07:30AM	Abeona Therapeutics Announces $50 Million Credit Facility (GlobeNewswire)
Dec-15-23 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-27-23 07:30AM	Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA) (GlobeNewswire) +11.60%
Nov-17-23 10:09AM	Abeona Therapeutics Inc. (NASDAQ:ABEO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 04:29AM	Q3 2023 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -5.56%
Nov-13-23 12:23PM	Abeona Therapeutics Inc (ABEO) Reports Q3 2023 Financial Results and Advances in Commercial ... (GuruFocus.com) +10.02%
07:41AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments (GlobeNewswire)
Nov-01-23 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-26-23 07:30AM	Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire) +9.84%
Sep-12-23 12:48PM	3 Biotech Blockbusters to Turn $5,000 Into $50,000 (InvestorPlace)
07:30AM	Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer (GlobeNewswire)
Sep-07-23 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-30-23 07:30AM	Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission (GlobeNewswire) +5.60%
Aug-11-23 07:41AM	ABEO: On Track to File BLA in 3Q23... (Zacks)
Aug-08-23 08:27AM	Abeona Therapeutics: Q2 Earnings Snapshot (AP Finance)
07:30AM	Abeona Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-28-23 07:30AM	Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023 (GlobeNewswire) +5.37%
Jul-19-23 08:30AM	Abeona Therapeutics Joins Rare Disease Company Coalition (GlobeNewswire)
Jul-07-23 08:30AM	Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jul-03-23 08:45AM	Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +6.95%
Jun-09-23 07:30AM	Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101 (GlobeNewswire)
Jun-01-23 07:30AM	Abeona Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 08:00AM	ABEO: Additional Phase 3 VIITAL Data Presented at ISID Meeting (Zacks Small Cap Research)
May-25-23 12:27AM	Q1 2023 Abeona Therapeutics Inc Earnings Call and Portfolio Update Conference Call (Thomson Reuters StreetEvents)
May-22-23 07:30AM	Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023 (GlobeNewswire)
May-16-23 09:00AM	Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (GlobeNewswire)
May-13-23 08:15AM	Abeona Therapeutics First Quarter 2023 Earnings: US$0.54 loss per share (vs US$3.59 loss in 1Q 2022) (Simply Wall St.)
May-11-23 07:54AM	Abeona Therapeutics: Q1 Earnings Snapshot (AP Finance) -7.19%
07:30AM	Abeona Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
07:00AM	Abeona Therapeutics Announces Additional Phase 3 VIITAL Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting (GlobeNewswire)
Apr-18-23 07:15AM	ABEO: Initiating Coverage of Abeona Therapeutics Inc.; Using Gene Therapy to Treat Orphan Diseases (Zacks Small Cap Research)
Apr-10-23 07:30AM	Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (GlobeNewswire)
Mar-31-23 06:22AM	Companies Like Abeona Therapeutics (NASDAQ:ABEO) Could Be Quite Risky (Simply Wall St.)
Mar-29-23 07:30AM	Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-24-23 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants (GlobeNewswire) +11.52%
Mar-16-23 07:30AM	Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting (GlobeNewswire)
Mar-14-23 07:30AM	Abeona Therapeutics Announces Update on AAV Ophthalmology Program (GlobeNewswire)
Nov-14-22 07:30AM	Abeona Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -5.47%
Nov-08-22 02:28PM	Cantor Bullish On Abeona Saying Recent Trial Data 'Best Case Scenario' (Benzinga)
Nov-03-22 12:44PM	Abeona Therapeutics Touts Positive Data From Pivotal EB-101 Study In Blistering Skin Disorder (Benzinga) -13.23%
07:31AM	Abeona Therapeutics Announces $35 Million Private Placement Financing (GlobeNewswire)
07:30AM	Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL Study of EB-101 (GlobeNewswire)
Oct-19-22 07:30AM	Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire) -8.09%
Oct-04-22 07:30AM	Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire)
Sep-22-22 07:30AM	Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit (GlobeNewswire) -9.22%
Sep-13-22 07:30AM	Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference (GlobeNewswire)
Sep-08-22 08:48AM	10 Best Penny Stocks to Buy in September (Insider Monkey)
Aug-11-22 07:30AM	Abeona Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire) +12.02%
Jul-20-22 07:30AM	Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Jun-24-22 10:08AM	F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm (Zacks) -8.94%
Jun-13-22 01:27PM	FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy (Zacks) -6.18%
Jun-10-22 03:30PM	FDA Committee Recommends bluebird's (BLUE) CALD Therapy (Zacks)
Jun-08-22 01:21PM	bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy (Zacks) +8.49%
Jun-06-22 02:04PM	AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half (Zacks)
07:30AM	Abeona Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
Jun-01-22 02:25PM	BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug (Zacks) -7.84%
May-31-22 02:27PM	Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe (Zacks)
May-25-22 02:29PM	Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease (Zacks)

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Alvino Mark	Director	Jun 18 '24	Sale	4.51	25,890	116,764	36,926	Jun 20 04:30 PM
Silverstein Christine Berni	Director	Jun 18 '24	Sale	4.51	25,821	116,453	62,063	Jun 20 04:30 PM
Alland Leila	Director	May 16 '24	Buy	4.71	11,000	51,799	82,857	May 20 08:30 AM
Seshadri Vishwas	Chief Executive Officer	Apr 25 '24	Buy	3.20	10,000	32,000	538,260	Apr 29 08:30 AM
Charles Faith L.	Director	Apr 26 '24	Buy	3.28	7,550	24,764	78,323	Apr 29 08:30 AM
O'Malley Brendan M.	SVP, General Counsel	Apr 25 '24	Buy	3.24	8,600	27,864	188,718	Apr 26 08:30 AM
Vazzano Joseph Walter	Chief Financial Officer	Apr 25 '24	Buy	3.14	5,608	17,609	233,868	Apr 26 08:30 AM
Seshadri Vishwas	Chief Executive Officer	Feb 06 '24	Buy	4.39	20,000	87,800	528,260	Feb 07 08:30 AM
Alvino Mark	Director	Jan 17 '24	Sale	5.11	7,084	36,199	62,816	Jan 22 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABEO

Abeona Therapeutics Inc

Upgrade your FINVIZ experience